In a patient with monoclonal gammopathy of renal significance and 50% clonal plasma cells in the bone marrow, what is the diagnosis?

This patient has Multiple Myeloma, not MGRS

With 50% bone marrow plasmacytosis, this patient meets the diagnostic criteria for multiple myeloma and therefore cannot be classified as MGRS. The diagnosis has progressed beyond monoclonal gammopathy of renal significance to overt hematologic malignancy requiring myeloma-specific treatment protocols 1.

Why This is Multiple Myeloma

The key diagnostic threshold is >60% bone marrow plasma cells, which is a myeloma-defining event even without other CRAB criteria (hypercalcemia, renal impairment, anemia, bone lesions) 1. While this patient has 50% plasmacytosis—just below that threshold—they still likely meet criteria for multiple myeloma through one of these pathways:

Diagnostic Algorithm:

1. Check for myeloma-defining events:

   • Bone marrow plasma cells ≥60% (this patient has 50%)
   • Serum involved:uninvolved free light chain ratio >100
   • ≥1 focal bone lesions on MRI
   • Any CRAB features (the renal impairment itself may qualify)

2. If bone marrow plasma cells are ≥10% AND monoclonal protein is present:

   • With 50% plasma cells, this far exceeds the 10% threshold
   • The presence of renal damage (cast nephropathy is a myeloma-defining event) 1
   • This combination indicates symptomatic myeloma requiring treatment

Critical Distinction from MGRS

MGRS is explicitly defined as having <10% monoclonal bone marrow plasma cells 1. The consensus definition states that MGRS applies only when "the underlying B cell or plasma cell clone does not cause tumour complications or meet any current haematological criteria for specific therapy" 1.

Once the haematological condition progresses to overt MM, these diseases are no longer considered MGRS and must be managed according to myeloma-specific protocols 1.

Management Implications

• This patient requires multiple myeloma treatment protocols, not MGRS-directed therapy
• The high plasma cell burden (50%) indicates significant disease requiring aggressive intervention
• Standard myeloma therapy should be initiated immediately to prevent progression and preserve remaining renal function
• The renal involvement should be characterized but treated as myeloma-associated kidney disease

Common Pitfall to Avoid

Do not be misled by the initial presentation as "MGRS"—the bone marrow biopsy revealing 50% plasmacytosis fundamentally changes the diagnosis. The term MGRS was initially considered but is now excluded by the high clonal burden. This is precisely why bone marrow biopsy is essential in the MGRS workup—to exclude overt malignancy 2.